Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids): Avoidance of surgery ‐ patients still meeting the criteria for surgery At end of
It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes avoidance of surgery ‐ patients still meeting the criteria for… compared with placebo (on top of topical steroids) (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids) Avoidance of surgery ‐ patients still meeting the criteria for surgery At end of · patients with severe chronic rhinosinusitis with nasal polyps It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes avoidance of surgery ‐ patients still meeting the criteria for… compared with placebo (on top of topical steroids) (very low certainty). Biologics for chronic rhinosinusitis (2021) · Cochrane Headline outcomes only | RR 0.78 [0.64, 0.94] | 2 studies · 135 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.